The game called STAT+ deals with the myths and financial aspects of Novo Nordisk. The article is part of The Readout news from the field of biotechnology. It includes news like Avadel Pharmaceuticals' up to $2.1 billion acquisition of Alkermes for a sleep drug. Arcturus Therapeutics announced interim results of a study of an mRNA treatment for cystic fibrosis, where there was no improvement in lung function over 28 days. Summit Therapeutics raised $500 million in a private placement, more than half bought by insiders, including the co-CEO. Startups like Wego and Zepbound are proposing new ways to finance expensive drugs directly for employers without insurance. Other news includes Novo Nordisk's deal with Aspect Biosystems for cell therapies for diabetes and new data on their Alzheimer's drug.[1][2][6]